+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
66.7600
4.4916
4.4295
.0246
4.9107
10.2978
High
92.1707
2.6409
No
Yes
Yes
No
Yes
Yes
0.6
No
Yes
Yes
Yes
Isobavachromene (CAS No.: 52801-22-6) is a naturally occurring chalcone compound, mainly isolated from the traditional Chinese medicinal herb Psoralea corylifolia L. As a natural product with significant biological activity, psoralene chalcone shows promising potential in multiple pharmacological effects such as antibacterial and antitumor properties, and has gradually become a hot topic in pharmacological research of natural products in recent years. Its unique chemical structure endows it with multi-target regulatory capabilities, especially in tumor-related signaling pathways, providing a theoretical and experimental basis for the development of novel anti-tumor drugs.
This review aims to systematically summarize the chemical structure and physicochemical properties, plant origin and extraction methods, pharmacological activity and mechanism of action of psoralene chalcone, druggability evaluation, and pharmacokinetic characteristics. Combined with current research progress, it explores its clinical application prospects and development trends, providing references for further research and drug development.
Psoralene chalcone belongs to the chalcone class of compounds, with the chemical formula C20H18O5 and a molecular weight of 322.3600. Its structural feature is a typical 1,3-diketostyreneone backbone, containing multiple hydroxyl and methoxy substituents, which imparts strong bioactivity. The LogP value of psoralene chalcone was 4.4916, indicating good lipophilusibility, which facilitates cell membrane penetration; TPSA (topological pole surface area) was 66.76 Ų, indicating good balance between polar and nonpolar environments. Low water solubility (0.0246 mg/mL) suggests limited solubility in the aqueous phase, which may affect its bioavailability.
Additionally, psoralene chalcone has a high blood-brain barrier penetration ability, demonstrating its potential application value in treating central nervous system diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test result was 0.6, indicating that the compound has a low genotoxicity risk and a solid safety foundation.
Psoralea corylifolia mainly comes from the leguminous plant Psoralea corylifolia L., which is widely used in traditional Chinese medicine to treat skin diseases, osteoporosis, and other conditions. Psoralea seeds are rich in various chalcone compounds, with psoralene chalcone being one of the important active components.
The extraction method typically uses organic solvent extraction combined with chromatography separation technology. Common extraction solvents include ethanol, methanol, and their aqueous solutions, which are used for ultrasound-assisted extraction or reflux extraction to improve extraction efficiency. The crude extract undergoes separation and purification steps such as silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC), ultimately yielding high-purity psoralene chalcone. In recent years, supercritical CO2 extraction and molecular blotting technologies have also been applied to the efficient extraction and purification of this compound, significantly improving yield and purity.
As a natural antimicrobial, psoralene chalcone exhibits good inhibitory effects against various Gram-positive and Gram-negative bacteria. In vitro experiments showed that it exhibited low minimum inhibitory concentrations (MIC) against common pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, and E. coli, suggesting its potential as an anti-infective drug. Its antibacterial mechanism may involve multiple pathways including cell membrane disruption, inhibition of protein synthesis, and disruption of cellular metabolism.
Psoralene chalcone exhibits significant antiproliferative and pro-apoptotic effects across various tumor cell lines. Research shows that this compound can inhibit tumor cell proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and is active against various tumor types such as breast, lung, and liver cancer.
In addition, psoralene chalcone also demonstrates anti-angiogenesis and anti-metastasis potential, inhibiting tumor growth and spread by regulating various signaling molecules in the tumor microenvironment.
The antitumor mechanism of psoralene chalcone involves multiple molecular targets and signaling pathways, demonstrating its multi-target regulatory characteristics.
MCL1 and BCL2: As anti-apoptotic proteins, MCL1 and BCL2 play key roles in tumor cell survival. Isosoralene chalcone promotes mitochondrial pathway-mediated apoptosis by downregulating the expression of these two proteins.
STAT3: The STAT3 signaling pathway plays an important role in tumor cell proliferation, immune evasion, and drug resistance. Psoralene chalcone can inhibit STAT3 phosphorylation and nuclear translocation, block its transcriptional activity, and suppress tumor growth.
MMP2: Matrix metalloproteinase 2 is involved in the degradation and metastasis of the tumor cell matrix. This compound reduces the aggressive ability of tumor cells by inhibiting MMP2 activity.
TOP1 and TOP2A :D NA topoisomerases are important enzymes for cell proliferation. Psoralene chalcone inhibits the activities of TOP1 and TOP2A, blocks DNA replication and transcription, and induces tumor cell death.
HIF1A: Hypoxia-inducing factor 1α regulates tumor cells' adaptability in low-oxygen environments. Psoralene chalcone inhibits HIF1A expression, hindering tumor hypoxia adaptation and angiogenesis.
MAPK1: The MAPK signaling pathway is involved in cell proliferation and differentiation. This compound affects tumor cell growth and apoptosis by modulating MAPK1 activity.
ESR1 and CYP19A1: Estrogen receptor 1 and aromatase play key roles in hormone-dependent tumors. Psoralalene chalcone regulates these two targets to influence hormone signaling pathways and inhibit tumor cell proliferation.
In summary, psoralene chalcone exerts its anti-tumor effects through multi-target and multi-pathway synergistic effects, demonstrating strong pharmacological activity and therapeutic potential.
The druggability evaluation of psoralene chalcone indicates promising prospects for drug development. Its molecular weight is moderate (322.36 Da), conforming to the Lipinski rule, with a LogP value of 4.49, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and distribution in vivo. TPSA is 66.76 Ų, indicating moderate polarity and favorable for oral absorption.
Low water solubility (0.0246 mg/mL) may limit its oral bioavailability and requires formulation optimization or structural modification. The high penetration ability of the blood-brain barrier suggests its potential application value in the treatment of central nervous system diseases. hERG channel inhibition negative, reducing the risk of cardiotoxicity. Ames trial results showed that it carries a low risk of genotoxicity and is relatively safe.
In terms of pharmacokinetics, current research is relatively limited, and metabolic pathways in vivo have not been fully elucidated. Preliminary data indicate that this compound has good stability and distribution characteristics in vivo, but its bioavailability and metabolic kinetics parameters still require further systematic study.
As a natural product with multiple pharmacological activities, psoralene chalcone demonstrates broad clinical application potential. Its antibacterial activity makes it a promising candidate for new anti-infective drugs, especially in the context of increasingly severe antibiotic resistance, where developing new antimicrobial agents is of great significance.
In the field of anti-tumors, psoracrylene chalcone regulates tumor cell proliferation, apoptosis, and metastasis through multiple targets, offering new approaches for tumor treatment. In particular, its regulation of key molecules such as STAT3, MCL1, and BCL2 may overcome the resistance issues of traditional chemotherapy drugs and enhance treatment outcomes.
Future research should focus on in-depth analysis of its pharmacokinetic characteristics, structural optimization to improve water solubility and bioavailability, and the development of combination drug strategies based on its multi-target mechanism. At the same time, systematic toxicological evaluations and preclinical studies are being conducted to lay a solid foundation for clinical translation.
In addition, by utilizing modern drug design technologies such as computer-aided drug design (CADD) and nano drug delivery systems, the efficacy and safety of psoralene chalcone are expected to be further enhanced, driving its advancement toward clinical application.
As a natural chalcone compound derived from traditional Chinese medicine Psoralea, with its unique chemical structure and multi-target pharmacological activity, it demonstrates broad research and application prospects in the fields of antibacterial and anti-tumor properties. Its excellent druggability parameters and safety foundation provide strong support for new drug development.
Although our understanding of its mechanism of action and pharmacokinetics is still incomplete, with advances in molecular biology and medicinal chemistry, psoralene chalcone is expected to become an important candidate molecule for the development of natural product drugs. In the future, through multidisciplinary collaboration and deep exploration of its potential, new opportunities will be provided for the modernization and precision treatment of natural medicines.
Shenshuai
Wenjing
Hedandan
